Is ketamine beneficial for controlling seizures, especially refractory status epilepticus?

Ketamine is NOT recommended in established guidelines for controlling seizures, but emerging evidence suggests potential benefit specifically for refractory and super-refractory status epilepticus when standard therapies fail.

Guideline-Based Recommendations

The 2014 ACEP Clinical Policy provides clear treatment algorithms for refractory status epilepticus (RSE) that do NOT include ketamine 1:

• Level A (Must): Administer additional antiepileptic medication after benzodiazepine failure
• Level B (Should): Use phenytoin, fosphenytoin, or valproate as second-line agents
• Level C (May): Consider levetiracetam, propofol, or barbiturates as alternatives

Notably absent from these recommendations is ketamine, despite the guideline being comprehensive in addressing RSE management. The 2024 systematic review of clinical practice guidelines similarly does not list ketamine among standard RSE treatments 2.

Critical FDA Safety Concern

The FDA label explicitly warns that ketamine may LOWER the seizure threshold when combined with theophylline or aminophylline 3. Additionally, the label describes "enhanced muscle tone and spasms resembling a partial motor or generalized motor seizure" as a known adverse effect during administration 3. This creates a theoretical concern about pro-convulsant properties.

Emerging Research Evidence

Despite guideline absence and FDA warnings, recent research shows promising results:

Efficacy Data

A 2026 meta-analysis of 388 patients demonstrated 64% seizure cessation rate (95% CI 49%-76%) with ketamine in RSE/SRSE 4. This represents substantial efficacy when conventional therapies have failed.

Key findings from recent systematic reviews:

• Overall seizure termination rate of 56% (95% CI: 51-61%) across 10 studies 5
• Similar efficacy in adults (59%) and children (50%) 5
• Earlier administration (within 3.2 days vs 4.3 days) associated with better outcomes 4
• Discontinuation due to adverse events was rare (0.7%, 3/55 patients) 4

Safety Profile

Ketamine offers distinct advantages over traditional anesthetics:

• Does not suppress respiratory drive like propofol or barbiturates 6
• 71.4% of non-intubated patients with refractory seizures responded without requiring intubation 6
• May reduce ICU length of stay and prevent intubation-related morbidity 7

Dosing Considerations

Critical threshold identified: doses <0.9 mg/kg/hr are ineffective 7. Typical regimens include:

• Initial bolus: 0.9 mg/kg 6
• Maintenance infusion: 2.5 ± 1.4 mg/kg/hr 4
• Duration: approximately 5 days 4

Clinical Algorithm for Ketamine Use

When to Consider Ketamine:

1. After failure of guideline-recommended therapies (benzodiazepines + second-line agents like valproate/phenytoin/levetiracetam)

2. In RSE/SRSE when:

   • Patient requires anesthetic therapy but hemodynamic instability limits propofol/barbiturates
   • Avoiding intubation is clinically desirable
   • Other anesthetics have failed

3. Timing matters: initiate within 12 hours of SE onset when possible 7, though benefit extends to later administration

Contraindications:

• Concurrent theophylline or aminophylline use 3
• Situations where sympathomimetic effects are dangerous

Monitoring Requirements:

• Blood pressure (both hypo- and hypertension occur in ~30-40% of patients) 6
• Respiratory status (though depression is less common than with other anesthetics)
• Continuous EEG to assess seizure cessation

Common Pitfalls

Do not use ketamine as first- or second-line therapy—this contradicts established guidelines and lacks supporting evidence. The guideline-recommended sequence (benzodiazepines → phenytoin/valproate/levetiracetam → anesthetics) should be followed first 1.

Do not underdose—maintenance rates below 0.9 mg/kg/hr are ineffective 7. Start with adequate dosing rather than titrating up slowly.

Do not delay if considering ketamine—earlier administration correlates with better outcomes 4, 7. Once the decision is made to use ketamine for RSE/SRSE, prompt initiation is preferable.

Do not assume ketamine replaces other anesthetics—it may be used adjunctively or when others fail, but propofol and barbiturates remain Level C recommendations with more established evidence 1.

Bottom Line

Ketamine has no role in routine seizure management per current guidelines but represents a viable rescue option for RSE/SRSE when standard therapies fail, particularly when hemodynamic stability or avoiding intubation are priorities. The evidence base is growing but consists primarily of retrospective studies. Use ketamine as a third-line or later agent, ensure adequate dosing (≥0.9 mg/kg/hr maintenance), and initiate early once the decision is made. The 2024-2026 research suggests ketamine's role may expand, but prospective trials are needed before guideline incorporation.